

March 11, 2015



CymaBay Therapeutics to Announce Fourth Quarter and Year-End 2014 Financial Results and Business Update on Wednesday, March 18, 2015

NEWARK, CA -- (Marketwired) -- 03/11/15 -- CymaBay Therapeutics, Inc.(NASDAQ: CBAY), today announced that it will host a conference call and live audio webcast on Wednesday, March 18 at 4:15 p.m. Eastern Time (1:15 p.m. Pacific Time) to discuss the Company's financial results for the quarter and year ended December 31, 2014 and to provide a general business update.

Conference Call Details

To access the live conference call, please dial (877) 407-8913 from the U.S. and Canada, or (201) 689-8201 internationally.

To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at <http://ir.cymbay.com/events>. A replay of the webcast will be available on the Company's website for 14 days following the live event.

About CymaBay

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in multiple Phase 2 gout studies. In gout patients, arhalofenate is intended to prevent painful flares in joints while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. CymaBay's second product candidate, MBX-8025 is a potent, selective, orally active PPAR δ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay is in the process of initiating a pilot study of MBX-8025 in patients with homozygous familial hypercholesterolemia.

For additional information about CymaBay visit www.cymbay.com.

Contact:
Sujal Shah
CymaBay Therapeutics, Inc.
(510) 293-8800
investors@cymbay.com

Source: CymaBay Therapeutics